Abstract:Background Severe selenium (Se) deficiency, as in Keshan disease, is associated with a fatal form of heart failure (HF), preventable and reversible with Se supplementation. Recent studies have identified Se deficiency as highly prevalent, up to 70%, among patients with HF, and associated with a poorer prognosis. Observational data suggest that Se concentrations <100 μg/L in HF patients and selenoprotein P (SELENOP) concentrations <4.1 mg/L are associated with increased mortality and hospital readmissions. Further, in recent studies, natural autoantibodies (aAb) towards SELENOP have been detected with the potential to disrupt transportation mechanisms. While the evidence does not yet support Se supplementation for HF patients in clinical practice, it does justify the initiation of large, well-designed randomized controlled trials (RCTs). Purpose To assess and confirm the previously reported high prevalence of Se deficiency, measured by both Se and SELENOP concentrations in HF patients and exploring the prevalence of aAb to SELENOP. This will provide a rationale for further, adequately powered and designed, studies of Se supplementation in HF patients. Methods A total of 527 blood samples were obtained from a nationwide Swedish HF biobank, sourced from various hospitals. In those samples; serum Se concentrations in 455 samples using mass spectrometry, SELENOP concentrations in 520 samples using an immunoassay, and prevalence of aAb to SELENOP in 513 samples using an immunoluminometric assay were analyzed. In addition, SELENOP concentrations in 320 HF patients from a Swedish single-center study were analysed. Results The study population had a mean age of 70.3 (±11.8) years (30.5% women). Prevalence of Se deficiency was higher than previously reported. In the national HF registry, the median Se concentration was 75 μg/L and Se concentrations below 100 μg/L were found in 426 (93%) samples. SELENOP concentrations had a median of 3.5 mg/L, corresponding to ~80 μg/L Se, with 80.5% of subjects below SELENOP-concentration of 4.3 mg/L (corresponding to ~100 μg/L Se). In the confirmatory single-center study, the SELENOP median concentration was 3.1 mg/L, corresponding to Se concentrations of ~70 μg/L and SELENOP -concentrations below 4.3 mg/L (corresponding to approximately 100 μg/L Se) were observed in 89.4% of the study population. Further, aAb to SELENOP were prevalent in 9.7% of the population, compared to approximately 1% in healthy subjects. Conclusion This pilot study demonstrates a high prevalence of suboptimal Selenium status in Swedish HF patients which further underscores the need for suitably designed intervention studies to address the efficacy and safety of Se supplementation which can possibly constitute an inexpensive, safe and readily available treatment option for HF patients.

A pilot study investigating the relationship between serum Se concentrations and Selenoprotein P activity at 28wks gestation in a high fish-eating sub-cohort of Seychellois pregnant women

Regulation of selenoprotein P concentration and expression by different sources of selenium in broiler breeders and their offspring

Selenium and at-risk pregnancy: challenges and controversies

Systematic study of the selenium fractionation in human plasma from a cancer prevention trial using HPLC hyphenated to ICP-MS and ESI-MS/MS

Effect of Different Selenium Sources on Productive Performance, Serum and Milk Se Concentrations, and Antioxidant Status of Sows.

Different Sources of Maternal Selenium Affect Selenium Retention, Antioxidant Status, and Meat Quality of 56-Day-old Offspring of Broiler Breeders.

Effects of Selenium Sources and Levels on Reproductive Performance and Selenium Retention in Broiler Breeder, Egg, Developing Embryo, and 1-Day-Old Chick

Effects of Sow Diet Supplemented with DL-Selenomethionine on Growth Performance of Offspring

Selenium speciation studies in cancer patients to evaluate the responses of biomarkers of selenium status to different selenium compounds

Effects of Different Selenium Sources and Levels on the Physiological State, Selenoprotein Expression, and Production and Preservation of Selenium-Enriched Eggs in Laying Hens

Effect of Different Selemethionine Forms and Levels on Performance of Breeder Hens and Se Distribution of Tissue and Egg Inclusion

Maternal metabolic syndrome and selenium: Endocrine energy balance during early programming

The Protective Effects of Different Sources of Maternal Selenium on Oxidative Stressed Chick Embryo Liver

Maternal Dietary Supplementation with Two Sources of Selenium Affects the Mortality and the Antioxidative Status of Chick Embryo at Different Developmental Periods

Selenium Levels and Their Association with Thyroid Autoimmunity and Severe Preeclampsia in Pregnancy: Insights from A Prospective Ideal Breast Milk Cohort Study

Serum Iodine as a Potential Individual Iodine Status Biomarker: A Cohort Study of Mild Iodine Deficient Pregnant Women in China

Effects of Different Forms and Levels of Selenomethionine on Productive Performance and Antioxidant Status of Broiler Breeders and Its Offspring

Selenium Discrepancies in Fetal Bovine Serum: Impact on Cellular Selenoprotein Expression

Selenium supplementation and pregnancy outcomes

The Effect of Selenium Supplementation on Clinical Outcomes, Metabolic Profiles, and Pulsatility Index of the Uterine Artery in High-Risk Mothers in Terms of Preeclampsia Screening with Quadruple Test: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Selenium, selenoprotein P and autoantibodies to selenium transport proteins in Swedish heart failure patients - a pilot study in preparation for a randomized supplementation trial